Biohaven Pharma (BHVN) Tops Q4 EPS by 28c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($0.90), $0.28 better than the analyst estimate of ($1.18).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Sysco raises mid-term targets, unveils $500M AI efficiency program
• Ryanair cancels 260 flights, faces up to $6 million in losses amid UK disruption
• Expand Energy (EXE) PT Raised to $147 at Raymond James